Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cerevel Therapeutics Holdings, Inc. (CERE)
|
Add to portfolio |
|
|
|
| Price: |
$10.10
| | Metrics |
| OS: |
156.7
|
M
| |
|
|
| Market cap: |
$1.58
|
B
| |
|
|
|
Net cash:
|
$615
|
M
| |
$3.92
|
per share
|
|
EV:
|
$968
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($67.7)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-05-20 | Dec-31-19 |
| Revenues | 0.0 | 0.0 | 161.9 | 0.0 | 103.3 | 0.0 |
| Revenue growth | | | 56.7% | | | |
| Cost of goods sold | 0.0 | 0.0 | 323.7 | 0.0 | 206.6 | 0.0 |
| Gross profit | 0.0 | 0.0 | -161.9 | 0.0 | -103.3 | 0.0 |
| Gross margin | | | -100.0% | | -100.0% | |
| Selling, general and administrative | 0.0 | 220.1 | | 149.1 | | 83.5 |
| General and administrative | 0.0 | | 58.2 | | 45.8 | |
| EBIT | 0.0 | -221.5 | -220.1 | 0.0 | -149.1 | 0.0 |
| EBIT margin | | | -136.0% | | -144.3% | |
| Pre-tax income | 0.0 | -225.3 | -225.3 | -152.2 | -152.2 | -128.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | 0.0 | -225.3 | -225.3 | -152.1 | -152.1 | -128.4 |
| Net margin | | | -139.2% | | -147.3% | |
| |
| Diluted EPS | | ($1.65) | ($1.56) | ($2.07) | ($2.42) | ($2.90) |
| Shares outstanding (diluted) | | 136.6 | 144.3 | 73.6 | 63.0 | 44.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|